182 related articles for article (PubMed ID: 26646960)
1. [Individualized treatment for ovarian cancer may become possible].
Kjölhede P; Dahm-Kähler P; Tholander B; Åvall Lundqvist E
Lakartidningen; 2015 Dec; 112():. PubMed ID: 26646960
[TBL] [Abstract][Full Text] [Related]
2. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
3. Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status.
Gadducci A; Guarneri V; Peccatori FA; Ronzino G; Scandurra G; Zamagni C; Zola P; Salutari V
J Ovarian Res; 2019 Jan; 12(1):9. PubMed ID: 30691488
[TBL] [Abstract][Full Text] [Related]
4. PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.
Smith HJ; Walters Haygood CL; Arend RC; Leath CA; Straughn JM
Gynecol Oncol; 2015 Oct; 139(1):59-62. PubMed ID: 26303225
[TBL] [Abstract][Full Text] [Related]
5. PARP Inhibitors in Epithelial Ovarian Cancer: State of Art and Perspectives of Clinical Research.
Gadducci A; Guerrieri ME
Anticancer Res; 2016 May; 36(5):2055-64. PubMed ID: 27127105
[TBL] [Abstract][Full Text] [Related]
6. Olaparib in the treatment of ovarian cancer.
Washington CR; Richardson DL; Moore KN
Future Oncol; 2019 Oct; 15(30):3435-3449. PubMed ID: 31478762
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.
Cannistra SA; Matulonis UA; Penson RT; Hambleton J; Dupont J; Mackey H; Douglas J; Burger RA; Armstrong D; Wenham R; McGuire W
J Clin Oncol; 2007 Nov; 25(33):5180-6. PubMed ID: 18024865
[TBL] [Abstract][Full Text] [Related]
8. The safety of antiangiogenic agents and PARP inhibitors in platinum-sensitive recurrent ovarian cancer.
Lorusso D; Fontanella C; Maltese G; Lepori S; Tripodi E; Bogani G; Raspagliesi F
Expert Opin Drug Saf; 2017 Jun; 16(6):687-696. PubMed ID: 28471247
[TBL] [Abstract][Full Text] [Related]
9. Safety evaluation of olaparib for treating ovarian cancer.
Lheureux S; Bowering V; Karakasis K; Oza AM
Expert Opin Drug Saf; 2015 Aug; 14(8):1305-16. PubMed ID: 26051946
[TBL] [Abstract][Full Text] [Related]
10. Poly (ADP-ribose) polymerase inhibitors: on the horizon of tailored and personalized therapies for epithelial ovarian cancer.
Ratner ES; Sartorelli AC; Lin ZP
Curr Opin Oncol; 2012 Sep; 24(5):564-71. PubMed ID: 22759740
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy for ovarian cancer: an evidence-based approach.
Geisler JP; Manahan KJ; Wiemann MC
Minerva Ginecol; 2004 Dec; 56(6):539-45. PubMed ID: 15729206
[TBL] [Abstract][Full Text] [Related]
12. [Epithelial ovarian cancer].
Hilpert F; Krause G; Venhoff L; Kühnle E; Schem C; Maass N
Ther Umsch; 2007 Jul; 64(7):375-80. PubMed ID: 17948754
[TBL] [Abstract][Full Text] [Related]
13. Genetic and epigenetic heterogeneity of epithelial ovarian cancer and the clinical implications for molecular targeted therapy.
Bai H; Cao D; Yang J; Li M; Zhang Z; Shen K
J Cell Mol Med; 2016 Apr; 20(4):581-93. PubMed ID: 26800494
[TBL] [Abstract][Full Text] [Related]
14. Maintenance therapy for newly diagnosed epithelial ovarian cancer- a review.
Nag S; Aggarwal S; Rauthan A; Warrier N
J Ovarian Res; 2022 Jul; 15(1):88. PubMed ID: 35902911
[TBL] [Abstract][Full Text] [Related]
15. Advances in treatment of epithelial ovarian cancer.
Kikkawa F; Nawa A; Ino K; Shibata K; Kajiyama H; Nomura S
Nagoya J Med Sci; 2006 Jan; 68(1-2):19-26. PubMed ID: 16579172
[TBL] [Abstract][Full Text] [Related]
16. PARP inhibitors alone and in combination with other biological agents in homologous recombination deficient epithelial ovarian cancer: From the basic research to the clinic.
Gadducci A; Guerrieri ME
Crit Rev Oncol Hematol; 2017 Jun; 114():153-165. PubMed ID: 28477743
[TBL] [Abstract][Full Text] [Related]
17. PARP Inhibitors in Epithelial Ovarian Cancer.
Taylor KN; Eskander RN
Recent Pat Anticancer Drug Discov; 2018; 13(2):145-158. PubMed ID: 29205122
[TBL] [Abstract][Full Text] [Related]
18. Clinical Trials of Novel Targeted Therapies in Ovarian Cancer: Moving Beyond Poly ADP Ribose Polymerase (PARP) Inhibitors.
Guo Q; Yang Q; Li J; Liu G; Nikoulin I; Jia S
Curr Pharm Biotechnol; 2018; 19(14):1114-1121. PubMed ID: 30585545
[TBL] [Abstract][Full Text] [Related]
19. One year maintenance of carboplatin in patients with epithelial ovarian cancer--a phase II study.
Safra T; Kovner F; Barak N; Inbar MJ; Ron IG
Isr Med Assoc J; 2006 Jan; 8(1):27-9. PubMed ID: 16450747
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of primary and recurrent ovarian cancer].
Rosendahl M; Mosgaard BJ; Steffensen KD
Ugeskr Laeger; 2018 Jan; 180(4):. PubMed ID: 29393032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]